share_log

Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $54

Moomoo 24/7 ·  Mar 1 08:33

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $41 to $54.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment